You can have a decent standard cholesterol panel, exercise four days a week, and still carry a cardiovascular risk marker that was basically assigned at conception. That’s Lp(a), short for lipoprotein(a). If you’re a man over 45, this is one of the cleaner examples of why a normal-looking lab sheet can still miss the point.

The practical takeaway is simple: an Lp(a) test for men over 45 belongs on the once-in-a-lifetime list. Not because it’s trendy, and not because some longevity guy on the internet discovered a new acronym. Because major cardiology guidelines now recommend it for every adult, and because elevated Lp(a) can materially raise heart attack and stroke risk even when the rest of the usual story looks fine.

If you’ve already gone through a complete bloodwork panel for men over 50, think of Lp(a) as the inherited blind spot many standard panels still leave out.

What Is Lipoprotein(a) and Why Is It More Dangerous Than Regular LDL?

Lp(a) is an LDL-like particle with extra hardware attached. It carries apolipoprotein B like LDL does, but it also carries an added apolipoprotein(a) component. That extra piece is why researchers treat it as more than just another cholesterol number.

The National Heart, Lung, and Blood Institute describes Lp(a) as having the same harmful traits as LDL, plus additional features that make it more likely to promote plaque buildup, inflammation, and clotting. That’s the part that matters. Elevated Lp(a) is not just “bad cholesterol, but a little worse.” It is a different risk signal with multiple ways to cause trouble.

NHLBI also notes that roughly 20% to 30% of people worldwide have elevated Lp(a), which makes it the most common inherited cardiovascular risk factor. That prevalence matters because this is not a zebras-only lab marker for rare edge cases. It’s common enough that a lot of men carrying it have no idea they do.

Regular LDL still matters. So do ApoB, blood pressure, smoking status, diabetes, and the rest of the usual cardiovascular suspects. But Lp(a) deserves separate attention because it can help explain why one person with average-looking labs has an event early, while another person with a similar profile does not.

That is also why it fits naturally next to broader risk markers like inflammation markers hsCRP and homocysteine. None of these numbers should be read in isolation. But some deserve a dedicated look because the standard panel doesn’t capture them well. Lp(a) is one of them.

Why Lp(a) Matters Specifically for Men Over 45

Men over 45 are already entering the stretch where cardiovascular risk stops being theoretical. “I’ll deal with it later” is a young man’s hobby.

According to the American Heart Association, Lp(a) levels are about 70% to 90% genetically determined. That makes them more heritable than familiar risk factors like hypertension, diabetes, or obesity. In other words, you cannot infer your Lp(a) level from how disciplined you are, how lean you look, or how respectable your oatmeal routine has become.

The same American Heart Association summary cites a study of 6,238 adults ages 43 to 65 showing that people in the top 10% for Lp(a), defined as 216 nmol/L or higher, had nearly triple the risk of heart attack even when they had no other major risk factors. That’s the number that should get your attention. Nearly triple risk is not background noise.

This hits men over 45 in a particularly relevant window because premature cardiovascular disease is generally defined as an event before age 55 in men. So if you’re in your late 40s or early 50s and trying to figure out whether your risk picture is actually complete, Lp(a) is not a niche add-on. It’s one of the most important unanswered questions.

It also helps explain why some men who do plenty right still get surprised. Standard lipids may look manageable. Blood pressure may be fine. Fitness may be decent. And yet the inherited risk marker sitting outside the basic panel never got measured.

That’s one reason it makes sense to view Lp(a) alongside a bigger picture of cardiovascular and metabolic markers, including optimal biomarker ranges for men over 50. The goal is not to chase more lab work for its own sake. The goal is to reduce the number of obvious blind spots.

The 2026 Guidelines Changed Everything: Why an Lp(a) Test for Men Over 45 Is Now Hard to Ignore

March 13, 2026 is the date this stopped being optional-looking. On that date, the updated ACC/AHA/Multisociety dyslipidemia guideline was announced, and the American Heart Association Newsroom reported that Lp(a) measurement had been upgraded to a Class 1 recommendation for all adults.

Class 1 is not polite suggestion language. It means the evidence and expert consensus support doing it.

The same 2026 guideline classifies an Lp(a) level of 125 nmol/L or 50 mg/dL or higher as a risk-enhancing factor. The American Heart Association Newsroom summary notes that level is associated with about a 1.4-fold higher long-term risk of heart attack or stroke. At 250 nmol/L or higher, the risk is at least doubled.

That changes the conversation for men who have been told some version of, “Your cholesterol is okay, so you’re probably fine.” Maybe. But if Lp(a) was never measured, that conclusion was built on incomplete information.

This is where a lot of readers lose patience with medicine, sometimes fairly. For years, Lp(a) existed in the category of “important, but not routinely ordered.” Now the consensus is clearer: test once, know the number, and use it to interpret the rest of the risk picture more intelligently.

Harvard Health Publishing put the same point more plainly in its March 2026 coverage of the new cholesterol guidelines: Lp(a) is not part of a standard lipid panel, but it now belongs on the list of tests adults should get at least once. That is the sort of change worth noticing because it affects what you ask for at your next visit.

How to Test: What to Ask Your Doctor and What the Numbers Mean

This part is refreshingly straightforward. You ask for an Lp(a) blood test specifically, because it is not included in a routine lipid panel.

Harvard Health Publishing notes that labs may report Lp(a) in either nmol/L or mg/dL, with nmol/L generally preferred because it reflects particle concentration more directly. The headline threshold from the 2026 guideline is simple enough to remember: 125 nmol/L or 50 mg/dL and above is elevated.

Once you have the number, you usually do not need to keep repeating the test. The American Heart Association and Harvard Health both emphasize that Lp(a) stays relatively stable through adult life because it is largely genetically determined. This is not like triglycerides after a vacation full of restaurant meals. You are not tracking a moving target every quarter.

What you can ask your doctor is:

• Was Lp(a) measured in nmol/L or mg/dL?
• Does my result cross the elevated threshold?
• How does this change the interpretation of my LDL, ApoB, blood pressure, and family history?
• Should first-degree relatives be tested too?

That last question matters because the 2026 guideline recommends cascade screening. If your Lp(a) is elevated, first-degree relatives have a 50% chance of being elevated as well. For a marker this heritable, family testing is not overkill. It’s basic pattern recognition.

If your usual doctor resists ordering it, the better move is not to argue for 20 minutes in an exam room. It’s to ask directly whether the practice can order Lp(a), and if not, whether there is a lab pathway they recommend. For men who already use direct-access testing, this is also one of the reasons guides on how to get a full blood workup without a doctor’s order tend to stay popular.

What to Do If Your Lp(a) Is High: Current Management and Emerging Therapies

This is the part where internet nonsense usually enters the chat. Elevated Lp(a) is serious, but the answer is not a mystery supplement stack with a heroic margin.

The Cleveland Clinic Journal of Medicine reviewed current clinical practice in November 2025 and made the key point clearly: lifestyle changes do not directly lower Lp(a) in a meaningful way. That’s frustrating, but better to know it than to waste six months pretending flaxseed solved a genetic risk marker.

What does help right now is reducing the rest of the cardiovascular risk burden aggressively and intelligently. That usually means tighter LDL lowering, careful blood pressure control, and a harder look at the total risk picture rather than fixation on one number. The same Cleveland Clinic Journal review notes that PCSK9 inhibitors can reduce Lp(a) by roughly 20% to 30%, though they are not approved specifically as Lp(a)-targeted therapies.

Low-dose aspirin may also be worth discussing in selected higher-risk patients, but that is a clinician-level decision because bleeding risk matters. This is one of those areas where the honest answer is conditional, not macho.

The good news is that the treatment pipeline is real. The Cleveland Clinic Journal of Medicine reports that three RNA-based therapies, pelacarsen, olpasiran, and lepodisiran, are in Phase 3 trials, with major results expected in 2026 and 2027. These agents have shown Lp(a) reductions in the range of 80% to 95% or more in trials, with dosing intervals from monthly to every six months depending on the drug.

So the sensible current position is not hopelessness and not false certainty. It is this:

• Measure Lp(a) once so you know whether the risk is present.
• If it is elevated, treat the rest of the cardiovascular picture with less complacency.
• Watch the RNA therapy pipeline closely, because this is one of the more credible near-term developments in preventive cardiology.

That’s not as emotionally satisfying as “take this capsule and fix everything.” It is, however, a lot closer to reality.

Frequently Asked Questions

If my standard cholesterol panel came back normal, do I still need an Lp(a) test?

Yes. Standard lipid panels do not include Lp(a), and both Harvard Health Publishing and the 2026 ACC/AHA/Multisociety guideline coverage make that distinction explicit. A normal routine panel does not answer the Lp(a) question.

Can diet, exercise, or supplements lower my Lp(a) level?

Not directly in any reliable way based on current evidence. The Cleveland Clinic Journal of Medicine review says lifestyle changes do not meaningfully lower Lp(a), which is why management focuses on lowering overall cardiovascular risk rather than pretending the marker itself is easily moved.

If I have high Lp(a), should my children and siblings be tested?

Probably yes, or at minimum the question is worth raising promptly. The 2026 guideline recommends cascade screening because first-degree relatives have about a 50% chance of elevated Lp(a) when one family member has it.

When will the new Lp(a)-lowering drugs be available to patients?

There is no approved Lp(a)-specific drug yet. But pelacarsen, olpasiran, and lepodisiran are in Phase 3 trials, with major readouts expected in 2026 and 2027 according to the Cleveland Clinic Journal of Medicine.

Is this a test you repeat every year?

Usually no. Because Lp(a) is largely genetically determined and stays fairly stable across adult life, the American Heart Association and Harvard Health Publishing both describe it as a once-in-a-lifetime measurement for most adults unless a clinician has a specific reason to revisit it.

The bottom line is not complicated: if you’re a man over 45 and you have never had Lp(a) measured, there is a hole in your cardiovascular risk picture. The current evidence does not say every elevated result leads to disease, but it very clearly says this marker changes how risk should be interpreted.

One blood test will not make you immortal. It can, however, tell you whether your “everything looked fine” story was missing a page.

Sources

• American Heart Association. “Lipoprotein(a).” https://www.heart.org/en/health-topics/cholesterol/genetic-conditions/lipoprotein-a
• American Heart Association Newsroom. “ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol.” https://newsroom.heart.org/news/accaha-issue-updated-guideline-for-managing-lipids-cholesterol
• Cleveland Clinic Journal of Medicine. “Lipoprotein(a) in clinical practice: What clinicians need to know.” https://www.ccjm.org/content/92/11/679
• Harvard Health Publishing. “New cholesterol guidelines recommend Lp(a) blood test.” https://www.health.harvard.edu/heart-health/new-cholesterol-guidelines-recommend-lpa-blood-test
• NIH / National Heart, Lung, and Blood Institute. “Lipoprotein(a): What to know about elevated levels.” https://www.nhlbi.nih.gov/news/2024/lipoproteina-what-know-about-elevated-levels

Continue reading: Read the pillar — Biomarkers & Lab Testing

This article is for informational purposes only and is not financial advice. Consult a qualified professional for personalized guidance.